Bli medlem
Bli medlem

Du är här

2016-10-31

Elekta: USITC publishes initial determination in litigation dispute

STOCKHOLM, October 31, 2016 - An Administrative Law Judge of the
United States International Trade Commission (USITC) issued an
initial determination (a first decision) on October 27 in a
litigation dispute with Varian Medical Systems.

The judge dismissed Varian's infringement claims on patents related to
imaging enhanced radiotherapy and declared them not infringed by
Elekta or invalid due to prior art incorporated in patents
exclusively licensed by Elekta.

He further stated that certain parts of Elekta's radiotherapy
solutions are violating patents owned by Varian, predominantly
related to algorithms used in treatment planning software.

The judge's initial determination is being analyzed and several
grounds have been identified on which to seek review of this initial
determination before the USITC.

Elekta has previously filed parallel proceedings at the US Patent and
Trademark Office, which have been instituted, to declare these
patents invalid. Preliminary analysis is that there is a reasonable
likelihood of success in these cases.

This initial determination of the USITC will be subject to procedural
reviews within the USITC before any final determination is reached,
which will likely last until the end of Elekta's fiscal year
2016/2017.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta
AB

Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time
Johan Andersson, Director Investor Relations, Elekta AB
Tel: +46 8 587 25 415, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time
This is information that Elekta AB (publ) is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was
submitted for publication at 07:30 CET on October 31, 2016.

About Elekta
Elekta is a human care company pioneering significant innovations and
clinical solutions for treating cancer and brain disorders. The
company develops sophisticated, state-of-the-art tools and treatment
planning systems for radiation therapy, radiosurgery and
brachytherapy, as well as workflow enhancing software systems across
the spectrum of cancer care. Stretching the boundaries of science and
technology, providing intelligent and resource-efficient solutions
that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over
6,000 hospitals worldwide. Elekta employs around 3,600 employees
globally. The corporate headquarters is located in Stockholm, Sweden,
and the company is listed on NASDAQ Stockholm. Website:
www.elekta.com.

-----------------------------------------------------------
http://news.cision.com/elekta/r/usitc-publishes-initial-determination-in...
http://mb.cision.com/Main/35/2112113/582621.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.